GOALS: To understand patients' perceptions of factors which facilitate and hinder adherence to inform adherence-enhancing interventions. BACKGROUND: Adherence to antiviral therapy for hepatitis C viral infection is critical to achieving a sustained virological response. However, persistence with and adherence to antiviral regimens can pose challenges for patients that interfere with sustained virological response. STUDY: A qualitative analysis of 21 semistructured patient interviews using open-ended questions and specific follow-up probes was conducted. Interviews were audio-recorded, transcribed, and content-analyzed iteratively to determine frequent and salient themes. RESULTS: Three broad themes emerged: (1) missing doses and dose-timing errors; (2) facilitators of adherence; and (3) barriers to adherence. Open-ended questioning revealed few dose-timing deviations, but more specific probes uncovered several more occurrences of delays in dosing. Facilitators of adherence fell into 2 broad categories: (a) patient knowledge and motivation; and (b) practical behavioral strategies and routines. Facilitators were noted post hoc to be consistent with the Information-Motivation-Behavioral Skills Model of Adherence. Barriers to adherence involved changes in daily routine, being preoccupied with family or work responsibilities, and sleeping through dosing times. A few patients reported skipping doses due to side effects. Patients with previous hepatitis C virus treatment experience may have fewer dose-timing errors. Finally, a high level of anxiety among some patients was discovered regarding dosing errors. Emotional and informational support from clinical and research staff was key to assuaging patient fears. CONCLUSION: This qualitative study improves our understanding of patients' perspectives regarding adhering to hepatitis C treatment and can lead to the development of adherence-enhancing interventions.
GOALS: To understand patients' perceptions of factors which facilitate and hinder adherence to inform adherence-enhancing interventions. BACKGROUND: Adherence to antiviral therapy for hepatitis C viral infection is critical to achieving a sustained virological response. However, persistence with and adherence to antiviral regimens can pose challenges for patients that interfere with sustained virological response. STUDY: A qualitative analysis of 21 semistructured patient interviews using open-ended questions and specific follow-up probes was conducted. Interviews were audio-recorded, transcribed, and content-analyzed iteratively to determine frequent and salient themes. RESULTS: Three broad themes emerged: (1) missing doses and dose-timing errors; (2) facilitators of adherence; and (3) barriers to adherence. Open-ended questioning revealed few dose-timing deviations, but more specific probes uncovered several more occurrences of delays in dosing. Facilitators of adherence fell into 2 broad categories: (a) patient knowledge and motivation; and (b) practical behavioral strategies and routines. Facilitators were noted post hoc to be consistent with the Information-Motivation-Behavioral Skills Model of Adherence. Barriers to adherence involved changes in daily routine, being preoccupied with family or work responsibilities, and sleeping through dosing times. A few patients reported skipping doses due to side effects. Patients with previous hepatitis C virus treatment experience may have fewer dose-timing errors. Finally, a high level of anxiety among some patients was discovered regarding dosing errors. Emotional and informational support from clinical and research staff was key to assuaging patient fears. CONCLUSION: This qualitative study improves our understanding of patients' perspectives regarding adhering to hepatitis C treatment and can lead to the development of adherence-enhancing interventions.
Authors: Honghu Liu; Loren G Miller; Carol E Golin; Ron D Hays; Tongtong Wu; Neil S Wenger; Andrew H Kaplan Journal: Stat Med Date: 2007-02-28 Impact factor: 2.373
Authors: John G McHutchison; Thierry Poynard; Rafael Esteban-Mur; Gary L Davis; Zachary D Goodman; Joann Harvey; Mei-Hsiu Ling; Jean Jacques Garaud; Janice K Albrecht; Keyur Patel; Jules L Dienstag; Timothy Morgan Journal: Hepatology Date: 2002-03 Impact factor: 17.425
Authors: Joyce A Cramer; Anuja Roy; Anita Burrell; Carol J Fairchild; Mahesh J Fuldeore; Daniel A Ollendorf; Peter K Wong Journal: Value Health Date: 2008 Jan-Feb Impact factor: 5.725
Authors: Maida J Sewitch; Michal Abrahamowicz; Alan Barkun; Alain Bitton; Gary E Wild; Albert Cohen; Patricia L Dobkin Journal: Am J Gastroenterol Date: 2003-07 Impact factor: 10.864
Authors: Corrine I Voils; Heather A King; Carolyn T Thorpe; Dan V Blalock; Ian M Kronish; Bryce B Reeve; Colleen Boatright; Ziad F Gellad Journal: Dig Dis Sci Date: 2019-04-29 Impact factor: 3.487
Authors: Jacqueline A Richmond; Suzanne Sheppard-Law; Susan Mason; Sherryne L Warner Journal: Patient Prefer Adherence Date: 2016-12-13 Impact factor: 2.711
Authors: Oluwaseun Falade-Nwulia; Kathleen M Ward; Sean McCormick; Shruti H Mehta; Stephanie R Pitts; Stephanie Katz; Geetanjali Chander; David L Thomas; Mark Sulkowski; Carl A Latkin Journal: J Viral Hepat Date: 2020-03-02 Impact factor: 3.517